A study from the Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA has reported that “Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.”
This study was published in the June 25, 2014 Nature by Prof. Sher, Mayer-Barber Katrin D and others from the Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Treating Tuberculosis with an anti-cancer drug: Genistein inhibits the pathogenesis and progression of tuberculosis (Mtb) via up regulation of its target gene. This study suggests that Genistein, by down regulating its target gene, it may increase the levels of lipid inflammatory mediator Prostaglandin E2. Thereby, it may inhibit the pathogenesis and progression of tuberculosis. Together, this study suggests that pharmacological formulations encompassing “Genistein or its analogues” can be used to inhibit the progression of tuberculosis.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at info@genomediscovery.org
Citation: Boominathan, Treating Tuberculosis with an anti-cancer drug: Genistein inhibits the pathogenesis and progression of tuberculosis (Mtb) via up regulation of its target gene, 15/July/2014, 6.43 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
*Research cooperation
